PHILADELPHIA — Kristy Weber, MD, chief of Orthopaedic Oncology in the department of Orthopaedic Surgery at the Perelman School of Medicine at the University of Pennsylvania, and director of the Sarcoma Program in Penn’s Abramson Cancer Center, is now serving as the President of the Musculoskeletal Tumor Society (MSTS).
Founded in 1977, MSTS is the premier North American society related to the care of patients with musculoskeletal tumors with a focus on surgical treatment of benign and malignant bone and soft tissue tumors and metastatic bone disease. With a total of 275 members, MSTS aims to advance the science of orthopaedic oncology and promote high standards of patient care through excellence in education and research. Dr. Weber officially took over the role as President at the society’s annual meeting in October 2013 and will continue her term until the 2014 annual meeting.
“It’s been an honor to step into this role for the Society,” said Dr. Weber. “With a new strategic plan in place, this is a very important year for MSTS. It has been a privilege working with my esteemed colleagues who share the same passion for shaping orthopaedic oncology policies, and serving the needs of orthopaedic oncologists and their patients.”
In addition to her role as chief of Orthopaedic Oncology, Dr. Weber serves as the director of the Penn Sarcoma Program at the Abramson Cancer Center and specializes in the treatment of osteosarcomas, soft tissue tumors and limb salvage surgery. Her clinical interests include the treatment of patients with bone and soft-tissue tumors, utilizing limb-salvage techniques around the hip, pelvis, knee and shoulder, and her research interests have contributed significantly to the understanding of metastatic bone disease.
A graduate of the Johns Hopkins University School of Medicine, Dr. Weber continued her training at the University of Iowa, and subsequently completed a fellowship in orthopaedic oncology at the Mayo Clinic. Most recently, Dr. Weber was a Virginia & William Percy Professor of Orthopaedic Surgery and Oncology at Johns Hopkins Medicine, where she also served as the division chief of Orthopaedic Oncology and the director of the Sarcoma Program.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.